Nothing Special   »   [go: up one dir, main page]

SV2008002639A - Inhibidores macrociclicos del virus de hepatitis c ref. tip 101 slv - Google Patents

Inhibidores macrociclicos del virus de hepatitis c ref. tip 101 slv

Info

Publication number
SV2008002639A
SV2008002639A SV2006002639A SV2006002639A SV2008002639A SV 2008002639 A SV2008002639 A SV 2008002639A SV 2006002639 A SV2006002639 A SV 2006002639A SV 2006002639 A SV2006002639 A SV 2006002639A SV 2008002639 A SV2008002639 A SV 2008002639A
Authority
SV
El Salvador
Prior art keywords
optionally
ring
nitrogen
formula
inhibitors
Prior art date
Application number
SV2006002639A
Other languages
English (en)
Inventor
Kenneth Alan Simmen
Kock Herman Augustinus De
Pierre Jean-Marie Raboisson
Sandrine Marie Helene Vendeville
Lili Hu
De Vreken Wim Van
Gowan David Craig Mc
Abdellah Tahri
Dominique Louis Nestor Ghislain Surleraux
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37036843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2008002639(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of SV2008002639A publication Critical patent/SV2008002639A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

INHIBIDORES DE VHC DE FORMULA (I): (VER FORMULA); Y LOS N-ÓXIDOS, SALES Y FORMAS ESTEREOQUÍMICAMENTE ISOMÉRICAS DE ESTOS, EN LOS CUALES R1 ES ARILO O UN SISTEMA ANULAR SATURADO, PARCIALMENTE INSATURADO O COMPLETAMENTE INSATURADO DE 6 O 6 MIEMBROS, O UN SISTEMA ANULAR HETEROCICLICO BICICLO DE 8 A 12 MIEMBROS QUE CONTIENE UN NITRÓGENO, Y EN FORMA OPCIONAL UNO A TRES OXIGENO, AZUFRE O NITRÓGENO, DONDE DICHO SISTEMA ANULAR PUEDE ESTAR SUSTITUIDO EN FORMA OPCIONAL; L ES UN ENLACE DIRECTO, -O-, -O-ALCANDIILO C1-4-; -O-CO-, -O-C(=O)-NR5A- O -O-C(=O)-NR5A-ALCANDIILO-C1-4-; R2 ES HIDROGENO, -OR6, -C(=O)OR6, -C(=O)R7, -C(=O)NR5AR5B, -C(=O)NHR5C, -NR5AR5B, -NHR5C, -NHSOPNR5AR5B, -NR5ASOPR8, O -B(OR6)2; R3 Y R4 SON HIDROGENO O ALQUILO C1-6; O R3 Y R4 TOMADOS JUNTOS PUEDEN FORMAR UN ANILLO CICLOALQUILO C3-7; N ES 3, 4, 5 O 6; P ES 1 O 2; ARILO ES FENILO, NAFTILO, INDANILO, O 1, 2, 3, 4-TETRAHIDRONAFTILO, CADA UNO DE LOS CUALES PUEDE ESTAR SUSTITUIDO EN FORMA OPCIONAL HET ES UN ANILLO HETEROCICLO SATURADO, PARCIALMENTE INSATURADO O COMPLETAMENTE INSATURADO DE 5 O 6 MIEMBROS QUE CONTIENE 1 A 4 HETEROATOMOS SELECCIONADO CADA UNO EN FORMA INDEPENDIENTE DE NITRÓGENO, Y AZUFRE, QUE ESTA CONDENSADO EN FORMA OPCIONAL CON UN ANILLO BENCÉNICO, Y DONDE EL GRUPO HET COMO UN TODO PUEDE ESTAR SUSTITUIDO EN FORMA OPCIONAL; COMPOSICIONES FARMACEUTICAS QUE CONTIENEN COMPUESTOS (I) Y PROCESOS PARA PREPARAR LOS COMPUESTOS (I). TAMBIÉN SE PROPORCIONAN COMBINACIONES DISPONIBLES DE LOS INHIBIDORES DEL VHC DE FORMULA (I) CON RITONAVIR
SV2006002639A 2005-07-29 2006-07-29 Inhibidores macrociclicos del virus de hepatitis c ref. tip 101 slv SV2008002639A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05107067 2005-07-29
EP05107413 2005-08-11

Publications (1)

Publication Number Publication Date
SV2008002639A true SV2008002639A (es) 2008-07-23

Family

ID=37036843

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2006002639A SV2008002639A (es) 2005-07-29 2006-07-29 Inhibidores macrociclicos del virus de hepatitis c ref. tip 101 slv

Country Status (28)

Country Link
US (1) US7989471B2 (es)
EP (1) EP1912995B1 (es)
JP (1) JP5426163B2 (es)
KR (1) KR101074673B1 (es)
CN (1) CN101233137B (es)
AP (1) AP2473A (es)
AR (1) AR055104A1 (es)
AT (1) ATE517902T1 (es)
AU (1) AU2006274858B2 (es)
BR (1) BRPI0614670A2 (es)
CA (1) CA2617095C (es)
DK (1) DK1912995T3 (es)
EA (1) EA014646B1 (es)
GT (1) GT200600341A (es)
HK (1) HK1116772A1 (es)
IL (1) IL188283A (es)
JO (1) JO2768B1 (es)
MX (1) MX2008001395A (es)
MY (1) MY152153A (es)
NO (1) NO20081071L (es)
NZ (1) NZ564541A (es)
PE (1) PE20070221A1 (es)
SG (1) SG163613A1 (es)
SI (1) SI1912995T1 (es)
SV (1) SV2008002639A (es)
TW (1) TWI412534B (es)
UY (1) UY29705A1 (es)
WO (1) WO2007014919A1 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
WO2005073195A2 (en) 2004-01-30 2005-08-11 Medivir Ab Hcv ns-3 serine protease inhibitors
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
US7935670B2 (en) 2006-07-11 2011-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008008502A1 (en) 2006-07-13 2008-01-17 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008070358A2 (en) * 2006-11-16 2008-06-12 Phenomix Corporation N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100323953A1 (en) * 2007-01-08 2010-12-23 Phenomix Corporation Macrocyclic hepatitis c protease inhibitors
WO2008096002A1 (en) * 2007-02-08 2008-08-14 Tibotec Pharmaceuticals Ltd. Hcv inhibiting macrocyclic phosphonates and amidophosphates
EP2118091B1 (en) * 2007-02-08 2015-04-15 Janssen Sciences Ireland UC Pyrimidine substituted macrocyclic hcv inhibitors
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
CA2705803A1 (en) 2007-11-14 2009-05-22 Enanta Pharmaceuticals, Inc. Macrocyclic tetrazolyl hepatitis c serine protease inhibitors
WO2009079353A1 (en) 2007-12-14 2009-06-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic hcv serine protease inhibitors
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
WO2009117594A1 (en) 2008-03-20 2009-09-24 Enanta Pharmaceuticals, Inc. Fluorinated macrocyclic compounds as hepatitis c virus inhibitors
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009148923A1 (en) 2008-05-29 2009-12-10 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2009324643B2 (en) 2008-12-10 2014-08-28 Achillion Pharmaceuticals, Inc. New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201040181A (en) * 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
CN101987825B (zh) * 2009-07-31 2014-04-02 上海开拓者医药发展有限公司 一种2-氨基-3-甲基-4-甲氧基苯乙酮的制备方法
CA2769652A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
US8937041B2 (en) 2010-12-30 2015-01-20 Abbvie, Inc. Macrocyclic hepatitis C serine protease inhibitors
EP2658858A4 (en) 2010-12-30 2014-06-25 Enanta Pharm Inc MACROCYCLIC INHIBITORS OF HEPATITIS C SERINE PROTEASE PHENANTHRIDINE
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN104136453B (zh) * 2012-01-11 2018-01-12 艾伯维公司 用于制备hcv蛋白酶抑制剂的方法
CN104822682A (zh) 2012-10-08 2015-08-05 艾伯维公司 用于制备hcv蛋白酶抑制剂的化合物
SG11201502802PA (en) 2012-10-19 2015-05-28 Bristol Myers Squibb Co Hepatitis c virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
US9115175B2 (en) 2013-03-14 2015-08-25 Achillion Pharmaceuticals, Inc. Processes for Producing sovaprevir
US9227952B2 (en) 2013-03-15 2016-01-05 Achillion Pharmaceuticals, Inc. Sovaprevir polymorphs and methods of manufacture thereof
US9006423B2 (en) 2013-03-15 2015-04-14 Achillion Pharmaceuticals Inc. Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
WO2014145600A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
MA41812A (fr) * 2015-03-27 2018-01-30 Janssen Pharmaceuticals Inc Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1090914B1 (en) 1992-12-29 2003-01-02 Abbott Laboratories Retroviral protease inhibiting compounds
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
BR9708735A (pt) 1996-04-23 1999-08-03 Vertex Pharma Derivados de uréia como inibidores da enzina impdh
PL192280B1 (pl) 1996-10-18 2006-09-29 Vertex Pharma Inhibitory proteaz serynowych, a zwłaszcza proteazy wirusa NS3 zapalenia wątroby C, kompozycja farmaceutyczna i zastosowania
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
EP0966465B1 (en) 1997-03-14 2003-07-09 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
HUP0100100A3 (en) 1997-08-11 2001-12-28 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptide analogues, pharmaceutical compositions comprising thereof and their use
GB9818731D0 (en) * 1998-08-27 1998-10-21 Univ Portsmouth Compounds
EA004141B1 (ru) 1999-03-19 2004-02-26 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы фермента impdh
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
NZ575692A (en) 2002-04-11 2009-10-30 Vertex Pharma Inhibitors of Serine Proteases, Particularly Hepatitis C Virus NS3-NS4 Protease
DE602004019518D1 (de) * 2003-04-16 2009-04-02 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
US7125845B2 (en) * 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
WO2005073195A2 (en) 2004-01-30 2005-08-11 Medivir Ab Hcv ns-3 serine protease inhibitors
TWI375670B (en) * 2005-07-29 2012-11-01 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis c virus
PE20070343A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c

Also Published As

Publication number Publication date
DK1912995T3 (da) 2011-10-24
EA014646B1 (ru) 2010-12-30
UY29705A1 (es) 2007-05-31
KR20080041651A (ko) 2008-05-13
CA2617095C (en) 2014-05-13
HK1116772A1 (en) 2009-01-02
SG163613A1 (en) 2010-08-30
JP5426163B2 (ja) 2014-02-26
TWI412534B (zh) 2013-10-21
JP2009502882A (ja) 2009-01-29
GT200600341A (es) 2007-02-26
EP1912995A1 (en) 2008-04-23
AU2006274858A1 (en) 2007-02-08
MY152153A (en) 2014-08-15
SI1912995T1 (sl) 2011-11-30
BRPI0614670A2 (pt) 2011-04-12
CA2617095A1 (en) 2007-02-08
AR055104A1 (es) 2007-08-08
AU2006274858B2 (en) 2012-05-24
JO2768B1 (en) 2014-03-15
CN101233137B (zh) 2014-05-07
US20100240698A1 (en) 2010-09-23
KR101074673B1 (ko) 2011-10-19
MX2008001395A (es) 2008-04-16
IL188283A0 (en) 2008-04-13
ATE517902T1 (de) 2011-08-15
US7989471B2 (en) 2011-08-02
TW200745165A (en) 2007-12-16
AP2473A (en) 2012-09-24
PE20070221A1 (es) 2007-04-16
EP1912995B1 (en) 2011-07-27
CN101233137A (zh) 2008-07-30
WO2007014919A1 (en) 2007-02-08
NZ564541A (en) 2010-03-26
NO20081071L (no) 2008-04-25
IL188283A (en) 2016-12-29
EA200800484A1 (ru) 2008-06-30

Similar Documents

Publication Publication Date Title
SV2008002639A (es) Inhibidores macrociclicos del virus de hepatitis c ref. tip 101 slv
SV2008002642A (es) Inhibidores macrociclicos del virus de hepatitis c ref. pit 111 slv
CL2011002377A1 (es) Compuestos derivados de heterociclos triciclicos fusionados de anillo antraceno y bifenileno, inhibidores de proteína ns5a del virus de hepatitis c (vhc); composicion farmaceutica que los comprende; y uso del compuesto en la preparacion de un medicamento util en el tratamiento de hepatitis c.
GT200600165A (es) Derivados dihidrobenzofuranos y usos de los mismos
UY29016A1 (es) Analogos de dipeptidos inhibidores de la hepatitis c
PE20130375A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
PE20161573A1 (es) Ciclopropilamina como inhibidor de la lsd1
AR064416A1 (es) Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR075510A1 (es) Inhibidores del virus de la hepatitis c
NI200700270A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
SV2008002641A (es) Inhibidores macrociclicos del virus de hepatitis c ref. tip 138 slv
PA8789901A1 (es) Derivados de la 6-cicloamino-3-(piridazin-4-il)imidazol(1,2-b) priridazina, su preparación y su aplicación en terapéuta
CR6951A (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos.
AR055105A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
ES2422299T3 (es) Indoles (4,5-dihidro) indoles tricíclicos
CR10136A (es) Nucleósidos antivirales
PE20060556A1 (es) Derivados de urea ciclicos sustituidos con heterociclo como inhibidores de quinasa
PE20121157A1 (es) Compuestos heterociclicos como inhibidores de proteasas serinas
PE20141208A1 (es) Compuestos de piridazinona y su uso como inhibidores de daao
PE20170249A1 (es) Acidos carboxilicos heterociclicos como activadores de guanilato ciclasa soluble
PE20091439A1 (es) Compuestos triciclicos como antagonistas de crf
PE20080010A1 (es) Derivados de diazepina para el tratamiento de la depresion y composiciones farmaceuticas que los comprenden
PE20000011A1 (es) Combinacion eficaz para el tratamiento de la impotencia
PE20170295A1 (es) Compuestos de imidazopiridazina